Lataa...
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
Despite meaningful, incremental improvements in detection, local treatment and adjuvant systemic treatments for breast cancer, there remains a significant risk of late relapse in hormone receptor (HR)-positive disease. 5 years of tamoxifen or an aromatase inhibitor for all patients with HR-positive...
Tallennettuna:
| Julkaisussa: | Breast Care (Basel) |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
S. Karger GmbH
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527163/ https://ncbi.nlm.nih.gov/pubmed/28785180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000477956 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|